No Data
No Data
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $7.5
Humacyte Announces Symvess Cost-Saving Benefits In Journal Of Medical Economics; Supports Economic Value For Hospitals And Payers
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Cuts Target Price to $7.5
Humacyte's SYMVESS Launch and Strategic Positioning Drive Buy Rating
Humacyte Price Target Maintained With a $25.00/Share by D. Boral Capital
Humacyte Is Maintained at Buy by D. Boral Capital